Abstract:Background Reprogramming of amino acid metabolism is critical for tumor growth. We have reported that upregulation of pyrroline-5-carboxylate reductase 1 (PYCR1), a key enzyme in mitochondrial proline anabolism, contributes to gastric cancer (GC) progression and indicates poor survival. However, the PYCR1 expression profile in GC subtypes and the underlying mechanisms behind its upregulation, as well as the promotion of GC progression are not well-studied. Methods PYCR1 expression profiles in GC subtypes and stages of gastric carcinogenesis were assessed in different cohorts. Genetic alterations and epigenetic modulation in PYCR1 regulation were investigated in tumor tissues and GC cell lines. The effect of PYCR1 on GC progression was further investigated from the perspectives of mitochondrial function and intracellular metabolism. Results PYCR1 expression was significantly higher in intestinal-type GC and associated molecular subtypes in two independent GC cohorts. During the Correa cascade of gastric carcinogenesis, PYCR1 was continuously increased from normal gastric tissues to atrophic gastritis with or without intestinal metaplasia, through to dysplasia, and finally to cancerous lesions. Hypomethylation and p300-mediated H3K27ac acetylation activation in PYCR1 promotor synergistically facilitated PYCR1 transcription. PYCR1 depletion or overexpression attenuated or promoted GC cell proliferation, but did not have any effect on the cell cycle. PYCR1 inhibition decreased mitochondrial DNA copy number in GC cells, but had no effect on mitochondrial membrane potential, mitochondrial mass and oxidative stress response. Detection of intracellular metabolite profiles revealed that PYCR1 depletion had a significant effect on intracellular purine metabolism (hypoxanthine, inosine and adenosine monophosphate), which was associated with cell growth inhibition. Furthermore, depletion of PYCR1 restored mitochondrial networking via enhancing mitochondrial fusion, leading to inhibition of cell proliferation. Consistently, pharmacological enhancement with Mdivi-1 of mitochondrial fusion also brought about the similar effects. Conversely, PYCR1 overexpression promoted mitochondrial fission, contributing to tumor growth. Conclusions PYCR1 overexpression was heterogeneous in different GC subtypes, and an increase in PYCR1 was an early event in the multistep of gastric carcinogenesis. Epigenetic modulation synergistically contributes to PYCR1 upregulation in GC, resulting in tumor progression via enhancing mitochondrial fission and coupling with purine metabolic reprogramming. Collectively, PYCR1 might be a promising therapeutic target for GC.

SMYD5 methylation of rpL40 links ribosomal output to gastric cancer

SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development

SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression

Altered 5-Hydroxymethylcytosine Landscape in Primary Gastric Adenocarcinoma

SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk

PRMT5-dependent Transcriptional Repression of C-Myc Target Genes Promotes Gastric Cancer Progression.

Myelocytomatosis‐Protein Arginine N‐Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma

Abstract 5578: Multi-omics approach reveals a SMAD4-deficiency signature, translational reprogramming and synthetic lethality in esophageal adenocarcinom

SMPDL3B contributes to gastric adenocarcinoma cells progression by promoting the infiltration of M2 macrophages

IDDF2022-ABS-0083 Epigenetic Induction of Mitochondrial Proline Synthase PYCR1 Promotes Gastric Cancer Progression by Regulating Mitochondrial Dynamics and Purine Metabolism

SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner

O-GlcNAcylation Promotes YTHDF1 Cytosolic Localization and Colorectal Cancer Tumorigenesis

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

ALYREF-JunD-SLC7A5 axis promotes pancreatic ductal adenocarcinoma progression through epitranscriptome-metabolism reprogramming and immune evasion

Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer

Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment

Epigenetic Silencing of Mir-490-3p Reactivates the Chromatin Remodeler SMARCD1 to Promote Helicobacter Pylori-Induced Gastric Carcinogenesis.

SMYD Family Members Serve as Potential Prognostic Markers and Correlate with Immune Infiltrates in Gastric Cancer

Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis